Tune Therapeutics Secures Major Financing to Drive Epigenome Innovations
Leading epigenome editing company Tune Therapeutics has recently announced a significant achievement in its journey; the company has completed a financing round exceeding $175 million. This successful funding event has been led by prominent investors including New Enterprise Associates, Yosemite, Regeneron Ventures, and Hevolution Foundation, reflecting a strong belief in the potential of epigenetic therapies in revolutionizing treatment approaches.
Transformative Potential of Epigenetic Medicine
Dr. Charles Gersbach, Co-Founder of Tune Therapeutics, shared his excitement about the company's progress, noting how the foundation of their groundbreaking TEMPO epi-editing platform originated from his research at Duke University. Tune has marked a pivotal moment in the healthcare sector by applying epi-editing techniques to address common and chronic diseases. The enthusiastic support from investors has positioned the company to develop an array of new epi-editing therapies.
Advancing Key Programs
The newly acquired funding will specifically enhance the development of the company’s existing pipeline, prominently featuring Tune-401, an innovative epigenetic silencing drug targeting chronic Hepatitis B (HBV). Besides advancing Tune-401, the financing will also catalyze the progress of other gene, cell, and regenerative therapy initiatives currently underway at Tune, ultimately advancing their mission of leveraging the power of epigenetic therapies against common ailments.
Investor Insights on Company Growth
Reed Jobs, a founder and investor at Yosemite, expressed pride in the milestones achieved by Tune Therapeutics. Jobs credited the team’s focus on epigenetic medicine, which possesses a unique biological potency capable of significantly improving disease outcomes. He believes that the range of possibilities for epigenetic applications is extensive and will continue to grow as research advances.
Addressing Chronic Diseases
William Greene, Chief Investment Officer at Hevolution Foundation, shared his perspective on the current medical landscape. He pointed out that while modern medicine has significantly improved life expectancy, it has fallen short in addressing the quality of life. Greene highlighted the increasing frequency and severity of chronic age-related diseases and emphasized the need for transformative approaches like epigenetic editing to foster a new era in regenerative medicine.
A Leap Forward in Clinical Research
Since its inception in 2021, Tune Therapeutics has made remarkable progress with its innovative epigenome editing platform. The company gained notable recognition at the recent ASGCT conference, where it announced a notable achievement: the enduring suppression of a therapeutically relevant gene (PCSK9) in non-human primates achieved via genetic tuning. This gene repression has led to a sustained reduction in LDL cholesterol levels almost two years post the initial delivery of the epi-silencing construct.
Clinical Trials and Future Directions
Tune’s commitment to advancing treatment for chronic HBV has been further solidified as the company prepares to begin clinical trials in various regions, having received necessary approvals. Well-respected hepatologists will support these trials, guiding the company as it capitalizes on the momentum generated from its lead therapeutic program. This strategic move is expected to bolster the capabilities of their entire platform while accelerating the development of additional gene and cell therapy programs.
Strategic Growth Plans Ahead
Akira Matsuno, Co-Founder, President, and CFO of Tune Therapeutics, expressed gratitude to their investors, reflecting on the confidence they have demonstrated in Tune’s mission and strategy. Matsuno believes that with this renewed support, they will be strategically positioned to push forward their HBV clinical program, further invest in their platforms, and expand their therapeutic pipeline.
About Tune Therapeutics
Tune Therapeutics is dedicated to revolutionizing gene, cell, and regenerative therapies. The company utilizes its innovative genetic tuning platform, known as TEMPO, to enhance therapeutic applications targeting prevalent chronic diseases.
About Tune-401
Tune-401 represents an investigational product designed for combating Hepatitis B (HBV) infections. Leveraging the modular TEMPO platform, Tune-401 aims to epigenetically silence essential HBV genetic elements responsible for persistent infections. Cutting-edge lipid nanoparticle technology for the formulation has been provided by Acuitas Therapeutics Inc.
Frequently Asked Questions
What is Tune Therapeutics known for?
Tune Therapeutics is recognized for its pioneering work in epigenome editing, particularly in developing therapies to combat chronic diseases such as Hepatitis B.
How much financing has Tune Therapeutics secured?
Tune Therapeutics has successfully completed over $175 million in financing from various leading investors aimed at advancing its research programs.
What is the TEMPO platform?
The TEMPO platform is an innovative genetic tuning technology developed by Tune Therapeutics, designed for epigenetic editing of genes to treat chronic diseases effectively.
What is Tune-401?
Tune-401 is an investigational drug candidate specifically targeted at treating chronic Hepatitis B infections using state-of-the-art epigenetic silencing techniques.
What future plans does Tune Therapeutics have for clinical trials?
Tune Therapeutics is preparing to launch clinical trials in multiple locations and aims to accelerate its research programs and therapeutic pipeline as part of its growth strategy.
